Stage IVB Lung Cancer AJCC v8 Recruiting Phase 1 / 2 Trials for Telaglenastat (DB15232)

IndicationStatusPhase
DBCOND0111251 (Stage IVB Lung Cancer AJCC v8)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03831932Glutaminase Inhibitor CB-839 Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung CancerTreatment